US Surgical's $1 Billion Lesson and the Laparoscopic Revolution of the 90s
•February 12, 2026
0
Why It Matters
The episode shows that high‑risk regulatory bets can generate massive growth, but without robust operational safeguards, even billion‑dollar medtech firms can rapidly lose market leadership.
Key Takeaways
- •Off‑label trial sparked 1990s laparoscopic boom
- •CEO Leon Hirsch bet company on unproven technology
- •"Green Beret" sales force trained 40,000 surgeons worldwide
- •Just‑in‑time inventory error ceded market to Ethicon
- •Lesson: aggressive growth must balance supply chain resilience
Pulse Analysis
The US Surgical story underscores a timeless truth in medtech: breakthrough products often emerge from regulatory gray zones, but scaling them demands more than clinical enthusiasm. Lee Cohen’s discovery of an off‑label surgeon experiment turned a risky idea into a market‑defining laparoscopic platform, illustrating how early‑stage innovators must navigate FDA constraints while convincing leadership to fund unproven concepts. Companies that master this balance can achieve rapid revenue spikes, as evidenced by US Surgical’s $1.1 billion peak.
Equally critical was the company’s sales execution. By deploying a highly motivated "Green Beret" sales team, US Surgical created a learning ecosystem that educated 40,000 surgeons worldwide, embedding the technology into operating rooms and establishing a durable moat. This approach highlights the power of direct physician engagement and hands‑on training in medical device adoption—strategies that modern medtech firms replicate through digital simulators and hybrid sales models.
The eventual downfall serves as a cautionary tale about operational overreach. A just‑in‑time inventory strategy, while cost‑effective, left US Surgical vulnerable to supply disruptions, allowing competitors like Ethicon and J&J to capture market share. The lesson for today’s CEOs is clear: aggressive growth must be paired with resilient supply‑chain planning and inventory buffers, especially in regulated environments where product availability directly impacts patient outcomes and revenue continuity.
Original Description
In this episode, host Omar Khateeb launches the new US Surgical Series with legendary Lee Cohen. Lee, the former Senior Director of Laparoscopy, was the woman inside the company who discovered a surgeon’s illegal, off-label experiment and turned it into the laparoscopic revolution. She reveals how she convinced the brilliant CEO Leon Hirsch to bet the entire company on an idea that was technically against the law. Lee shares wild stories from the front lines, from fainting in her first open surgery to fighting her way as the only woman in a gritty Newark sales territory. She details the "Green Beret" sales culture, the explosive global launch that trained 40,000 surgeons, and the moment the company hit $1.1 billion in revenue. Finally, she exposes the fatal strategic mistake, the "Just in Time" inventory blunder, that handed the entire market to Ethicon and J&J, leading to the company's stunning collapse. This is the untold story of the people who built a medical empire and the costly lesson in how to lose it all.
Episode Breakdown:
00:00 – Intro: Why this MedTech conversation matters
02:03 – Lee Cohen’s background & career path
05:12 – Entering healthcare & early lessons learned
08:26 – What outsiders misunderstand about MedTech
11:04 – Building inside complex healthcare systems
13:47 – Why distribution wins in medical devices
16:18 – The underestimated power of sales teams
19:02 – Taking risk in regulated markets
21:36 – Product-market fit in healthcare vs tech
24:08 – What makes exceptional MedTech founders
26:41 – Scaling inside hospital ecosystems
29:15 – Capital allocation & long-term thinking
31:48 – Innovating within large incumbents
34:22 – Build vs acquire: Strategic decisions
36:55 – FDA, regulation & strategic timing
39:27 – Defending moats in surgical markets
42:03 – Platform strategy in MedTech
44:36 – The economics of surgical robotics
47:10 – Where real innovation is happening
49:42 – AI in devices: Practical vs hype
52:14 – Leadership vs operational excellence
54:48 – Scaling high-performance teams
57:20 – Common mistakes healthcare founders make
59:52 – Timing cycles in MedTech
01:02:24 – The future of surgical innovation
01:05:02 – Industry consolidation & capital flows
01:07:35 – Advice for young operators
01:10:06 – What separates great CEOs
01:12:38 – Long-term outlook for healthcare innovation
01:15:14 – Personal reflections & career insights
01:17:46 – Final lessons on building durable companies
01:20:18 – Closing thoughts & key takeaways
01:22:00 – Outro
Are you a medtech CEO in need of some marketing help attracting investors, growing sales pipeline, and more? Go to GrowMyMedtech.com to book time for a free analysis.
Subscribe to our Youtube Channel
Subscribe to our LinkedIn Newsletter
https://www.stateofmedtechpodcast.com/
Follow The State of MedTech on
LinkedIn https://www.linkedin.com/company/thestateofmedtech
Instagram https://www.instagram.com/stateofmedtech/
TikTok https://www.tiktok.com/@stateofmedtech
X https://twitter.com/StateofMedTech
Facebook https://www.facebook.com/stateofmedtech/
Follow Omar M. Khateeb on
LinkedIn https://www.linkedin.com/in/okhateeb/
Instagram https://www.instagram.com/omar.m.khateeb/
TikTok https://www.tiktok.com/@omarkhateebofficial
X https://twitter.com/OmarMKhateeb
Facebook https://www.facebook.com/OmarMKhateeb/
#medtech #healthcareinnovation #surgicalrobotics #medicaldevices #healthcareleadership
0
Comments
Want to join the conversation?
Loading comments...